Business Wire
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
📈
AI Sentiment
Highly Positive
9/10
- Home
- ESLA
as of 12-05-2025 4:00pm EST
$1.99
+$0.06
+3.11%
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Chart Type:
Time Range:
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 48.9M | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 243.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $3.15 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ESLA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 69.88%
69.88%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Estrella Immunopharma Inc. News
ESLA Breaking Stock News: Dive into ESLA Ticker-Specific Updates for Smart Investing
Compare ESLA vs Leading Stocks
See how ESLA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ESLA Estrella Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.